ROHDE-&-SCHWARZ
21.10.2020 15:02:11 CEST | Business Wire | Press release
In the past, the creation of software took about a year on average of development before being commercialized. Today, many organizations are adopting a continuous integration and deployment approach. Now, the cycle has become shorter, thanks in particular to DevOps, which relies on automation and the pooling of complementary skills to increase the added-value and responsiveness of companies.
The Rohde & Schwarz Cybersecurity strategy aims to help DevOps teams integrate application security right from the design phase, by integrating control capabilities within their APIs and applications. Rohde & Schwarz Cybersecurity has been offering Web Application Firewall (WAF) technologies for about twenty years. The company now makes its technologies consumable by developers. It offers tools that integrate into the environment and tools already existing and that use the same languages and technologies of the DevSecOps universe. It is in this context that Rohde & Schwarz Cybersecurity is launching R&S Trusted Application Factory.
Putting security at the heart of applications
R&S Trusted Application Factory is a solution for DevOps teams with the objective of providing security, simplicity and visibility.
- Security : By integrating security as close as possible to the application
- Simplicity : To simplify collaboration, the security solution must be integrated into the DevOps teams' universe. Thus, the same tools, languages and concepts must be used.
- Visibility : It is necessary to provide visibility to the various users and managers: developers, infrastructure and security. R&S Trusted Application Factory tracks the application from design to production execution, providing indicators on its security throughout its lifecycle.
The R&S Trusted Application Factory application security service is deployed as a container for each application. This container can therefore "evolve" at the same time as the application in Kubernetes or Docker clusters. It can therefore automatically adapt to the application load. It also accompanies the application and can be deployed on-demand as well as on the private or public cloud. All the services are managed from a SaaS administration console, which enables the security of the various applications to be monitored.
The solution is based on the concept of "Context Description" to improve the level of security. Indeed, the data specific to each application and available to the development teams are essential for the configuration of security. The type of persistence used, the programming language, the server operating system and the data formats make it possible to automatically adapt protection policies by invoking the appropriate engines. By taking all these elements into account, increased security and a reduced risk of false positives is achieved.
Rohde & Schwarz Cybersecurity
Rohde & Schwarz Cybersecurity is a leading IT security company that protects the digital assets of companies and public institutions worldwide from cyberattacks.
Rohde & Schwarz
Rohde & Schwarz is a leading supplier of solutions in the fields of test and measurement, broadcast and media, aerospace | defense | security and networks and cybersecurity.
R&S® is a registered trademark of Rohde & Schwarz GmbH & Co KG.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005500/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FuzeBox AI Named Founding Co-Author of SPUR Coalition Technical Committee on Verifying AI Content Use5.10.2026 15:00:00 CEST | Press release
A new technical committee will define how publishers can independently confirm AI companies' reports of content use. FuzeBox AI has been named by the SPUR Coalition, an international nonprofit of 37 news and media organizations, as one of four founding co-authors of its Evidence Profile Technical Committee, adopted Sept. 2, 2026, to draft an evidence profile for SPUR's Content Telemetry standard: a way for publishers to verify AI usage reports without depending on the reporting company's cooperation. Under SPUR's current standard, AI companies self-report their content use. A company that skips reporting leaves no record, and publishers can't check what they do receive. On July 10, 2026, FuzeBox proposed its Verified Provenance Telemetry Standard (VPTS): publishers seed content with detectable markers, then verify their appearance in AI outputs via an auditable ledger, with no change to SPUR's standard. Within 48 hours, three organizations filed related proposals: ProRata on usage magn
Mary Kay Introduces the K-Beauty Texture Edit5.10.2026 14:02:00 CEST | Press release
Special-Edition Korea-Made Skin Care Collection Launches In 40 Markets, Available While Supplies Last Mary Kay Inc.,the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, aspecial-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005600130/en/ Mary Kay's Special Edition K-Beauty Texture Edit is a trend-forward collection which includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel. (Image Credit: Mary Kay Inc.) Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.5.10.2026 14:00:00 CEST | Press release
Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing market1 GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subje
Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 13:24:00 CEST | Press release
The installation marks a significant step in the evolution of premium No/Low wines, where preserving aroma and sensory quality has become a defining industry priority. Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking exper
Croma-Pharma Expands Its Portfolio in Canada With saypha® lips Lidocaine and Exprecell™5.10.2026 13:12:00 CEST | Press release
Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom